Deep brain stimulation (DBS) currently comprises only about a quarter of the worldwide neuromodulation device market, but growth in this segment is strong. Both large and small competitors have targeted DBS, which has the potential to address a number of highly prevalent and underserved diseases and disorders.

The cardiac interventional suite has historically welcomed high-tech, cutting-edge tools. But with hospitals scrutinizing expenditures more closely than ever before, such tools must now prove themselves. Hospitals are now placing a premium on technologies that can improve safety, efficiency, and flexibility while streamlining workflow. A handful of companies are now offering products designed to meet these needs, and providers are starting to take notice.

South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.